

DAFTAR PUSTAKA

1. Decroli E. Prediabetes. 1st ed. Padang :Andalas University Press; 2022.p.83
2. Rooney MR, Fang M, Ogurtsova K, Ozkan B, Echouffo-Tcheugui JB, Boyko EJ, *et al.* Global prevalence of prediabetes. *Diabetes Care.* 2023;46(7):1388–94.
3. National Center for Chronic Disease Prevention and Health Promotion (US), Division of Diabetes Translation. National Diabetes Statistics Report, 2020: Estimates of Diabetes and Its Burden in the United States. Atlanta (GA): Centers for Disease Control and Prevention; 2020.
4. Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia. Hasil Utama Riset Kesehatan Dasar (Riskesdas) 2018. Jakarta: Kementerian Kesehatan Republik Indonesia; 2018.
5. PERKENI. Pengelolaan dan pengobatan diabetes melitus tipe 2 dewasa. Pedoman pengelolaan dan pencegah diabetes melitus tipe 2 di Indonesia. 2021;1:88.
6. Weiss R, Santoro N, Giannini C, Galderisi A, Umamo GR, Caprio S. Prediabetes in youths: mechanisms and biomarkers. *Lancet Child Adolesc Heal.* 2017;1(3):240–8.
7. Lee SH, Park SY, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies. *Diabetes Metab J.* 2022 Jan;46(1):15–37.
8. US Preventive Services Task Force. screening for prediabetes and type 2 diabetes: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2021;326(8):736–43.

9. Rezavitawanti R, Helda H. Central obesity as a risk factor for prediabetes. *Asian Journal of Social and Humanities*. 2024;2(9):2068–78.
10. Aras S, Ustunsoy S. Indices of central and peripheral obesity : anthropometric measurements and laboratory parameters of metabolic syndrome and thyroid function. *Balkan Med J*. 2015;32:414–20.
11. World Obesity Federation. World Obesity Atlas 2023. London: World Obesity Federation; 2023.
12. Kementerian Kesehatan Republik Indonesia. Survei Kesehatan Indonesia (SKI) 2023. Jakarta: Badan Kebijakan Pembangunan Kesehatan, Kementerian Kesehatan Republik Indonesia; 2023.
13. Arneth B. Mechanisms of insulin resistance in patients with obesity. *Endocrines*. 2024; 5(2):153–65.
14. Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? *Curr Opin Endocrinol Diabetes Obes*. 2012;19(2):81–7.
15. Li C, Xu W, Zhu Y, Wang S, Liu J, Li H. Association between visceral adiposity index and incidence of diabetic kidney disease in adults with diabetes in the United States. *Sci Rep*. 2024;14:69034.
16. Baik I. Optimal cutoff points of waist circumference for the criteria of abdominal obesity: comparison with the criteria of the International Diabetes Federation. *Circ J*. 2009;73(11):2068–75.
17. Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. *Exp Biol Med (Maywood)*. 2016;241(12):1323–31.
18. Branda F, de Almeida-Pititto, Ferreira, S.R.G., Diabetic kidney disease in

prediabetes, *Obesity Medicine*.2019; 19(1):1–18

19. Fontalvo JR, Soler MJ, Arnedo RD, Blackaller GN, Gonzalez RM *et al*. Prediabetes and CKD : Does a causal relationship exist. *Nefrlogia*. 2024 ; 44 (5) : 628–38.
20. Echouffo-Tcheugui JB, Narayan KM, Weisman D, Golden SH, Jaar BG. Association between prediabetes and risk of chronic kidney disease: a systematic review and meta-analysis. *Diabetic medicine: a journal of the British Diabetic Association*. 2016;33(12):1615–24
21. Wu T, Ding L, Andoh V, Zhang J, Chen L. The mechanism of hyperglycemia-induced renal cell injury in diabetic nephropathy disease: An Update. *Life (Basel)*. 2023 Feb 15;13(2):539
22. Daza-Arnedo R, Rico-Fontalvo J, Aroca-Martínez G, *et al*. Insulin and the kidneys: a contemporary view on the molecular basis. *Front Nephrol*. 2023;3:1133352.
23. Carro CG, Vergara A, Bermejo S, Azancot M, Sellares J, *et al*. A nephrologist perspective on obesity: from kidney injury to clinical management. *Sec Nephrol*. 2021;8(1):1–11.
24. Whaley-Connell A, Sowers JR. Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. *Kidney Int*. 2017 ; 92 (2) :313–23.
25. Fiseha T, Tamir Z. Urinary markers of tubular injury in early diabetic nephropathy. *Int J Nephrol*. 2016;2016:4647685
26. Viswanathan V, Sivakumar S, Sekar V, Umapathy D, Kumpatla S. Clinical significance of urinary liver-type fatty acid binding protein at various stages

- of nephropathy. *Indian journal of nephrology*. 2015; 25 (5) : 269–73.
27. Xu Y, Xie Y, Shao X, Ni Z, Mou S. L-FABP: a novel biomarker of kidney disease. *Clin Chim Acta*. 2015;445:85–90.
 28. International Diabetes Federation (IDF). International Diabetic Federation Diabetic Atlas 10th edition. IDF; 2021.
 29. Aamir AH, Ul-Haq Z, Mahar SA, Qureshi FM, Ahmad I, Jawa A, *et al*. Diabetes prevalence survey of pakistan (DPS-PAK): prevalence of type 2 diabetes mellitus and prediabetes using Hba1C: a population-based survey from pakistan. *BMJ Open*. 2019;9(2):1–9.
 30. Bansal N. Prediabetes diagnosis and treatment: A review. *World J Diabetes*. 2015;6(2):296.
 31. Wysham C, Shubrook J. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications. *Postgrad Med* [Internet]. 2020;132(8):676–86.
 32. Manaf A. Insulin : Mekanisme sekresi dan aspek metabolisme. Dalam: Setiati S, Alwi I, Sudoyo A, Simadibrata M, Setyohadi B, Syam A, ed. Buku Ajar Ilmu Penyakit Dalam Jilid III Edisi VI. Jakarta:Interna Publishing; 2014. 2350–4.
 33. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. *Physiol Rev*. 2018;98(4):2133–223.
 34. Amato MC, Giordano C. Visceral adiposity index : an indicator of adipose tissue dysfunction. *Int J Endocrinol*. 2014;14(1):1–7.
 35. Oussaada SM, van Galen KA, Cooiman MI, Kleinendorst L, Hazebroek EJ, *et al*. The pathogenesis of obesity. *Metabolism*. 2019;92(1):26–36.

36. Sultan A, Singh J, Howarth FC. Mechanisms underlying electro-mechanical dysfunction in the Zucker diabetic fatty rat heart: a model of obesity and type 2 diabetes. *Heart Failure Reviews*. 2020;25(5):1–8.
37. Hastuti J, Kagawa B, Byrne NM. Determination of new anthropometric cut-off values for obesity screening in Indonesian adults. *Asia Pac J Clin Nutr*. 2017;26(1):118–23.
38. Jin X, Qiu T, Li L, Yu R, Chen X *et al*. Pathophysiology of obesity and its associated diseases. *Acta Pharm Sin B*. 2023;13(6):2403–24.
39. Rett K, Gottwald-Hostalek U. Understanding prediabetes: definition, prevalence, burden and treatment options for an emerging disease. *Curr Med Res Opin*. 2019 ; 35(9):1529–34.
40. Pina AF, Borges DO, Meneses MJ, Branco P, Birne R, Henriques C, *et al*. Insulin: trigger and target of renal functions. *Front Cell Dev Biol*. 2020;8:519.
41. Artunc F, Schleicher E, Weigert C, Fritsche A, Stefan N *et al*. The impact of insulin resistance on the kidney and vasculature. *Nat Rev Nephrol*. 2016;12(12): 721–37.
42. Pereira M, Ricardo E, Elza M. Effect of insulin on proximal tubule handling of glucose: a systematic review. *J Diabetes Res*. 2020;2020:8492467.
43. Oguntibeju OO. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. *Int J Physiol Pathophysiol Pharmacol*. 2019;11(3): 45–63.
44. Carstensen M, Herder C, Kivimäki M, Jokela M, Roden M, *et al*. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years

- before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. *Diabetes*. 2010; 59(5) : 1222–7.
45. Wang Z, Shen XH, Feng WM, Ye GF, Qiu W *et al*. Analysis of Inflammatory Mediators in Prediabetes and Newly Diagnosed Type 2 Diabetes Patients. *J Diabetes Res*. 2016;79(6): 1277–85.
 46. Bose S, Maity C, Roy N. Inflammatory markers in prediabetics. *J. Evlolution Med. Dent. Sci*. 2016;5(35):2056–60.
 47. Agarwal, Hegde A, Yadav C, Ahmad A, Manjrekar PA, Poornima, Rukmini. Interleukin-6 in impaired fasting glucose. *Indian Journal of Biochemistry and Biophysics*. 2018;55 : 424–428.
 48. Ye, Jianping. “Mechanisms of insulin resistance in obesity.” *Frontiers of medicine*. 2013;7(1): 14–24
 49. Garcia UG, Vicente AB, Jebari S, Sebal AL, Siddiqi H, Uribe KB, *et al*. Pathophysiology of type 2 diabetes mellitus. *Int. J. Mol. Sci*. 2020;21(6275) : 1–34.
 50. Paz-Filho G, Mastronardi C, Bertoldi C, Wang KB, Wong ML *et al*. Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. *Arq Bras Endocrinol Metab*. 2012;56(9): 597–607.
 51. Baranowska-Jurkun A, Matuszewski W, Bandurska-Stankiewicz E. Chronic microvascular complications in prediabetic states: an overview. *J Clin Med*. 2020;9(10):3289.
 52. Wang Y, Jin M, Cheng CK, Li Q. Tubular injury in diabetic kidney disease : molecular mechanisms and potential therapeutic perspectives. *Front. Endrocinol*. 2023;14:1238927

53. Borderie G, Larroumet A, Baillet-Blanco L, Foussard N, Rigalleau V, Mohammedi K, *et al.* Advanced glycation end products predict loss of renal function and high-risk chronic kidney disease in type 2 diabetes. *Diabetes Care.* 2022;44:684–91.
54. Vallon, V., Thomson, S.C. The tubular hypothesis of nephron filtration and diabetic kidney disease. *Nat Rev Nephro.* 2020;16(1): 317–36.
55. Jiang Z, Wang Y, Zhao X, Cui H, Han M, Ren X, Gang X, Wang G. Obesity and chronic kidney disease. *Am J Physiol Endocrinol Metab.* 2023;324(1):24–41.
56. Ye M, Yang M, Dai W, Li H, Zhou X, Chen Y, *et al.* Targeting renal proximal tubule cells in obesity-related glomerulopathy. *Pharmaceuticals.* 2023;16:1256.
57. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. *J Am Soc Nephrol.* 2004;15:2792–800.
58. Hall JE, do Carmo JM, da Silva AA. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. *Circ Res.* 2015;116: 991–1006.
59. Thipsawat S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature. *Diabetes and Vascular Disease Research.* 2021;18(6):1–9.
60. Chen, C., Wang, C., Hu, C., Han, Y., Zhao, L *et al.* Normoalbuminuric diabetic kidney disease. *Front. Med.* 2017;11 (3):310–318.
61. Liu H, Feng J, Tang L. Early renal structural changes and potential

- biomarkers in diabetic nephropathy. *Front Physiol.* 2022;8(13):1–8
62. Jenkin K, Verty A, McAinch A, Hryciw, D. H. (2012). Endocannabinoids and the renal proximal tubule: An emerging role in diabetic nephropathy. *Int. J. Biochem. Cell Biol.* 2012;44 (11):2028–31.
 63. Ning M, Mao X, Niu Y, Tang B, Shen H. Usefulness and limitations of neutrophil gelatinase-associated lipocalin in the assessment of kidney disease. *Journal of laboratory and precision medicine.* 2018;3(1): 1–11.
 64. Geng, J., Qiu, Y., Qin, Z. *et al.* The value of kidney injury molecule 1 in predicting acute kidney injury in adult patients: a systematic review and Bayesian meta-analysis. *J Transl Med.* 2021;19:105
 65. Omozee, Eiya Bibiana *et al.* “Urinary N-acetyl-beta-d-glucosaminidase levels in diabetic adults.” *Journal of laboratory physicians*;2019;11(1): 1–4
 66. Gaffar, S.; Aathirah, A.S. Fatty-Acid-Binding Proteins: From Lipid Transporters to Disease Biomarkers. *Biomolecules.* 2023; 13(1): 1753.
 67. Shi J, Zhang Y, Gu W, Cui B, Xu M, Yan Q, Wang W, Ning G, Hong J. Serum liver fatty acid binding protein levels correlate positively with obesity and insulin resistance in Chinese young adults. *PLoS One.* 2012;7(11):1–6.
 68. Dayem S, El Bohy M, El Shehaby A. Value of the intrarenal arterial resistivity indices and different renal biomarkers for early identification of diabetic nephropathy in type 1 diabetic patients. *J Endocrinol Metab.* 2016; 29:273–9.
 69. Thi TN, Pham TTH, Nguyen TT, Nguyen HT, Tran VH, Nguyen HL, *et al.* Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients. *J Med Biochem.* 2020;39(2):224-30.

70. Ikemori A, Sugaya T, Yasuda T, Kawata T, Ota A, *et al.* Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. *Diabetes Care*. 2011 Mar;34(3):691–6
71. Ito H, Yamashita H, Nakashima M, Takaki A, Yukawa C *et al.* Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in normoalbuminuric patients with type 2 diabetes. *J Clin Med Res*. 2017;9(4):366–373.
72. Wolfrum, Christian *et al.* “Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors α - and γ -mediated gene expression via liver fatty acid binding protein: A signaling path to the nucleus.” *Proceedings of the National Academy of Sciences of the United States of America* 98.2001;98(1): 2323–28.
73. Yamamoto T, Noiri E, Ono Y, Doi K, Negishi K *et al.* Renal L-type fatty acid binding protein in acute ischemic injury. *Journal of the American Society of Nephrology*. 2007;18: 2894–902
74. Wiharjo K, Noormatany, Permana H, Rachmayati S. Perbedaan kadar liver fatty acid binding protein (L-FABP) urine pada penderita diabetes melitus tipe 2 dengan normoalbuminuria dan mikroalbuminuria. 2014;46(2):83–87.
75. Xu Y, Xie Y, Shao X, Ni Z, Mou S. L-FABP: A novel biomarker of kidney disease. *Clin Chim Acta*. 2015;20(445): 85–90.
76. Nakamura T, Takeshi S, Yasuhiro K, Yoshihiko U, Shiwor O *et al*; Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. *Diabetes Care*. 2005; 28 (11): 2728–32.

77. Centers for Disease Control and Prevention. *National Diabetes Statistics Report 2022*. Atlanta, GA: CDC; 2022.
78. Sadr MS, Moghaddam SJ, Bagheri M, Ghorbani A, Asgari M, Khosravi A, *et al*. Factors associated with pre-diabetes in Tehranian men and women: a population-based study. *PLoS One*. 2017;12(8):e0188898.
79. Tao LX, Yang K, Huang FF, Liu XT, Li X, Luo YX, *et al*. Association of waist circumference gain and incident prediabetes defined by fasting glucose: a seven-year longitudinal study in Beijing, China. *Int J Environ Res Public Health*. 2017;14(10):1208.
80. Liberty IA, Septadina IS, Mariana, Novita E, Amalia R, Ananingsih ES, *et al*. The characteristics and risk of obesity central and concomitant impaired fasting glucose: Findings from a cross-sectional study. *PLoS One*. 2024;19(6).
81. Ra JS, Park E, Park SY. Sex differences in factors associated with prediabetes: findings from the Korea National Health and Nutrition Examination Survey. *Osong Public Health Res Perspect*. 2022;13(3):183-192.
82. Park SE, Lee BW, Kim JH, Kim DJ, Kim NH, *et al*. Diabetes Fact Sheets in Korea 2024. *Diabetes Metab J*. 2025;49(1):24-33.
83. Tramunt B, Smati S, Grandgeorge N, Lenfant F, Arnal JF, Montagner A, *et al*. Sex differences in metabolic regulation and diabetes susceptibility. *Diabetologia*. 2020;63(3):453-461.
84. Wang L, Peng W, Zhao Z, Zhang M, Shi Z, Song Z, *et al*. Prevalence and treatment of diabetes in China, 2013–2018. *JAMA*. 2021;326(24):2498-506

85. Dal Grande A, Van Herck M, Breyer-Kohansal R, *et al.* Incidence of prediabetes and diabetes in a European longitudinal general population cohort: results from the Austrian LEAD Study. *J Diabetes Res.* 2025;2025:6692145
86. Shakya P, Shrestha A, Karmacharya BM, Shrestha A, Kulseng BE, Skovlund E, *et al.* Prediabetes and associated factors of prediabetic stages: a cross-sectional study among adults in Nepal. *BMJ Open.* 2022;12(12).
87. Oh MR, Jung SJ, Bae EJ, Park BH, Chae SW. Clinical characteristics and associated risk factors of prediabetes in the southwestern region of Korea from 2010–2019. *J Clin Med.* 2020;9(4):1114.
88. Kim JH, Kim EH. CT-based measurement of visceral adipose tissue volume as a reliable tool for assessing metabolic risk factors in prediabetes across subtypes. *Sci Rep.* 2023;13:20745.
89. Jin X, Qiu T, Li L, Yu R, Chen X *et al.* Pathophysiology of obesity and its associated diseases. *Acta Pharm Sin B.* 2023;13(6):2403–24.
90. Liu Y, Li J, Wu Y, Zhang H, Lv Q, perfo Y, *et al.* Classical impaired glucose tolerance should be divided into I-IGT and IGT+IFG according to risk of progression to diabetes: a systematic review and meta-analysis. *Front Endocrinol (Lausanne).* 2022;13:835460.
91. Liu, W.; Hua, L.; Liu, W.F.; Song, H.L.; Dai, X.W.; Yang, J.K. The prevalence of glucose metabolism disturbances in Chinese Muslims and possible risk factors: A study from northwest China. *Arq. Bras. Endocrinol. Metabol.* 2014, 58, 715–723.
92. Aekplakorn, W.; Tantayotai, V.; Numsangkul, S.; Sripho, W.; Tatsato, N.;

- Burapasiriwat, T.; Pipatsart, R.; Sansom, P.; Luckanajantachote, P.; Chawarokorn, P.; *et al.* Detecting prediabetes and diabetes: Agreement between fasting plasma glucose and oral glucose tolerance test in Thai adults. *J. Diabetes Res.* 2015.
93. Li M, Xu Y, Wang T, Zhang Y, Ma L, Gao J, *et al.* Trends in insulin resistance: insights into mechanisms and therapeutic targets. *Signal Transduction and Targeted Therapy.* 2022;7(1):216.
94. Li YY, Tong LP, Wu XD, Lin D, Lin Y, Lin XY, *et al.* Analysis of influencing factors and interaction of body weight and disease outcome in patients with prediabetes. *World J Diabetes.* 2023 Oct 15;14(10):1551-61.
95. Ghachem A, Chakor R, Ben Rejeb M, Jallouli M, Chouikha A, Maatoug J, *et al.* Differential clusters of modifiable risk factors for impaired fasting glucose, impaired glucose tolerance and newly diagnosed diabetes in adults: a cross-sectional study. *BMC Public Health.* 2019;19(1):1–9.
96. Goedecke JH, Nguyen KA, Kufe C, Masemola M, Chikowore T, Mendham AE, *et al.* Waist circumference thresholds predicting incident dysglycemia and type 2 diabetes in Black African men and women. *Diabetes Obes Metab.* 2022;24(5):918-27.
97. Jang KW, Hur J, Lee DW, Kim SR, Park JS, Kim H, *et al.* Metabolic syndrome, kidney-related adiposity, and renal microcirculation. *Biomedicines.* 2024;12(12):2706.
98. Kim TN, Park MS, Lim KI, Yang SJ, Yoo HJ, Kang HJ, *et al.* Metabolically unhealthy non-obese individuals: characteristics and clinical implications. *Yonsei Med J.* 2021;62(11):1021–1030.

99. Gupta AK, Johnson WD. Prediabetes and prehypertension in disease-free obese adults correlate with an exacerbated systemic proinflammatory milieu. *J Inflamm (Lond)*. 2010;7:36.
100. Blüher M. Metabolically healthy obesity. *Endocr Rev*. 2020;41(3):bnaa004.
101. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome—an allostatic perspective. *Biochim Biophys Acta*. 2010;1801(3):338-49.
102. Takagi A, Kusunoki Y, Ohigashi M, Osugi K, Inoue C, Inoue M, *et al*. Association between continuous glucose monitoring-derived glycemic control indices and urinary biomarkers of diabetic kidney disease: Hyogo Diabetes Hypoglycemia Cognition Complications study. *Acta Diabetol*. 2024;61(4):413-23.
103. Kubota Y, Higashiyama A, Marumo M, Konishi M, Yamashita Y, Okamura T, *et al*. Relationship of urinary liver-type fatty acid-binding protein with cardiovascular risk factors in the Japanese population without chronic kidney disease: the Sasayama study. *BMC Nephrol*. 2021;22(1):189
104. Zhang L, Chen C, Duan J, *et al*. Performance of urinary liver-type fatty acid-binding protein in detecting and predicting diabetic nephropathy: A systematic review and meta-analysis. *Front Med (Lausanne)*. 2022;9:914587.
105. Satta E, *et al*. Urinary L-FABP: A Novel Biomarker for Evaluating Diabetic Nephropathy. *Diabetes Metab Res Rev*. 2025;41:e123456
106. Kamiyo-Ikemori A, Ichikawa D, Matsui K, Yokoyama T, Sugaya T, Kimura K. Urinary L-type fatty acid-binding protein (L-FABP) as a new urinary

biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan.

Rinsho Byori. 2013;61(7):635-40.

Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P. Urinary liver-type fatty acid-binding protein predicts progression of diabetic nephropathy and mortality in type 1 diabetic patients. *Diabetes Care*. 2010;33(6):1320-4.

